About Merit Medical Systems, Inc.
https://www.merit.comMerit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy.
CEO
Martha Goldberg Aronson
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-05-06 | Forward | 5:4 |
| 2003-12-03 | Forward | 4:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 192
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Barrington Research
Outperform
Raymond James
Outperform
Baird
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
TUDOR INVESTMENT CORP ET AL
Shares:35M
Value:$2.86B
BLACKROCK INC.
Shares:8.91M
Value:$728.72M
BLACKROCK, INC.
Shares:8.7M
Value:$711.25M
Summary
Showing Top 3 of 484
About Merit Medical Systems, Inc.
https://www.merit.comMerit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $384.16M ▲ | $143.8M ▲ | $27.75M ▼ | 7.22% ▼ | $0.47 ▼ | $79.54M ▼ |
| Q2-2025 | $382.46M ▲ | $137.61M ▲ | $32.58M ▲ | 8.52% ▲ | $0.55 ▲ | $83.96M ▲ |
| Q1-2025 | $355.35M ▲ | $130.99M ▼ | $30.15M ▲ | 8.48% ▲ | $0.51 ▲ | $76.8M ▲ |
| Q4-2024 | $355.16M ▲ | $136.42M ▲ | $27.95M ▼ | 7.87% ▼ | $0.48 ▼ | $72.73M ▼ |
| Q3-2024 | $339.85M | $120.27M | $28.44M | 8.37% | $0.49 | $73.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $392.46M ▲ | $2.63B ▲ | $1.1B ▲ | $1.53B ▲ |
| Q2-2025 | $343.87M ▼ | $2.59B ▲ | $1.1B ▲ | $1.49B ▲ |
| Q1-2025 | $395.53M ▲ | $2.47B ▲ | $1.04B ▲ | $1.43B ▲ |
| Q4-2024 | $376.71M ▼ | $2.42B ▲ | $1.04B ▼ | $1.38B ▲ |
| Q3-2024 | $523.13M | $2.38B | $1.05B | $1.32B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.75M ▼ | $74.98M ▼ | $-24.07M ▲ | $-365K ▼ | $50.65M ▲ | $51.51M ▼ |
| Q2-2025 | $32.58M ▲ | $83.31M ▲ | $-143.35M ▼ | $4.35M ▼ | $-53.68M ▼ | $104.83M ▲ |
| Q1-2025 | $30.15M ▲ | $40.57M ▼ | $-29.64M ▲ | $6.96M ▲ | $18.83M ▲ | $19.05M ▼ |
| Q4-2024 | $27.95M ▼ | $68.74M ▲ | $-214.45M ▼ | $2.43M ▲ | $-146.51M ▼ | $64.51M ▲ |
| Q3-2024 | $28.44M | $47.33M | $-115.67M | $-47.57M | $-113.44M | $37.41M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Cardiovascular | $340.00M ▲ | $340.00M ▲ | $360.00M ▲ | $370.00M ▲ |
 Endoscopy | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $130.00M ▲ | $150.00M ▲ | $160.00M ▲ | $140.00M ▼ |
 UNITED STATES | $210.00M ▲ | $0 ▼ | $230.00M ▲ | $210.00M ▼ |
CEO
Martha Goldberg Aronson
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-05-06 | Forward | 5:4 |
| 2003-12-03 | Forward | 4:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 192
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Barrington Research
Outperform
Raymond James
Outperform
Baird
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
TUDOR INVESTMENT CORP ET AL
Shares:35M
Value:$2.86B
BLACKROCK INC.
Shares:8.91M
Value:$728.72M
BLACKROCK, INC.
Shares:8.7M
Value:$711.25M
Summary
Showing Top 3 of 484